Cite
HARVARD Citation
Fox, K. et al. (2022). Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. European heart journal. 8 (8), pp. 825-836. [Online].